Patents by Inventor Benjamin Thuma

Benjamin Thuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200148669
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: January 16, 2020
    Publication date: May 14, 2020
    Applicant: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Publication number: 20190321382
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 24, 2019
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Patent number: 10376531
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 13, 2019
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Publication number: 20190106412
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Applicant: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Patent number: 10174007
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: January 8, 2019
    Assignee: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Publication number: 20180296585
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: June 29, 2018
    Publication date: October 18, 2018
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Patent number: 10039778
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: August 7, 2018
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Publication number: 20180037575
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 8, 2018
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Patent number: 9809579
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 7, 2017
    Assignee: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Publication number: 20170183328
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: December 16, 2016
    Publication date: June 29, 2017
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Publication number: 20170165284
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 15, 2017
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Patent number: 9617293
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Publication number: 20160207953
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: April 7, 2016
    Publication date: July 21, 2016
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Patent number: 9340553
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 17, 2016
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Publication number: 20150329555
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: May 18, 2015
    Publication date: November 19, 2015
    Applicant: PFIZER INC.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Patent number: 7615651
    Abstract: Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R, R1, R2a, R2b, R3, R4, V, R6, R7, R8, R9, W and X are described herein.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: November 10, 2009
    Assignee: Pfizer Inc.
    Inventors: Roger B. Ruggeri, George T. Magnus-Aryitey, Benjamin A. Thuma